REGISTER: Hear how Fulcrum Metals (FMET) is board restructuring to support its strategic focus on Canada. Find out at the focusIR Feb Investor Webinar. Sign up here.

Less Ads, More Data, More Tools Register for FREE
Sponsored Content
Don't want ads? Click here
Sponsored Content
Don't want ads? Click here

MaxCyte flags full-year revenue at top end of expectations

Mon, 13th Jan 2025 14:34

(Sharecast News) - Cell-engineering platform technology company MaxCyte said in an update on Friday that it expected core revenue for the fourth quarter to range between $8.3m and $8.5m, up from $7.2m in the same period last year.

The AIM-traded firm said that for the full year, core revenue was projected at between $32.2m and $32.4m, reflecting an 8% to 9% increase from the $29.8m recorded in 2023.

It said it would report further details on strategic platform licence (SPL) programme-related revenue and total revenue in March.

MaxCyte said its total cash, cash equivalents, and investments as of 31 December were estimated at about $190m, exceeding the company's initial guidance of $175m and revised guidance of $185m.

That would represent a decline from $211m at the end of 2023, however.

"MaxCyte reported preliminary core revenue for 2024 at the high end of the updated guidance range provided," said president and chief executive officer Maher Masoud.

"The operating environment in the cell therapy industry is improving as we move into 2025; and we remain confident in the opportunity that exists for MaxCyte in the years ahead.

"In 2024, we increased the number of SPL customers by six, supported the commercial launch of the first non-viral gene edited cell therapy product approved by the FDA, and returned to healthy revenue growth while streamlining operations."

At 1225 GMT, shares in MaxCyte were up 3.13% at 361.99p.

Reporting by Josh White for Sharecast.com.

Related Shares

More News
12 Feb 2025 10:21

MaxCyte signs SPL deal with TG Therapeutics

(Sharecast News) - MaxCyte announced the signing of a strategic platform licence agreement with TG Therapeutics on Wednesday, granting the biopharmace...

12 Feb 2025 09:30

MaxCyte partners with TG Therapeutics on autoimmune cell therapy

(Alliance News) - MaxCyte Inc on Wednesday said it has signed a strategic platform licence with TG Therapeutics Inc to develop its autoimmune cell the...

30 Jan 2025 16:43

MaxCyte announces acquisition of SeQure Dx

(Sharecast News) - MaxCyte announced on Thursday that it has acquired SeQure Dx, a specialist in on-target and off-target editing assessment services ...

30 Jan 2025 13:55

MaxCyte buys gene therapy analytics firm SeQure Dx

(Alliance News) - MaxCyte Inc on Thursday said it has acquired SeQure Dx Inc, as it looks to improve its gene therapy testing process.

Free Investment Tools

Register for FREE

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.